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ABSTRACT
Introduction: Saxagliptin added to metformin
extended release (XR) and uptitrated metformin
XR were evaluated for their impact on daily
glucose measurements and their tolerability in
patients with type 2 diabetes mellitus (T2DM)
inadequately controlled with metformin
monotherapy.
Methods: Patients aged 18–78 years on
metformin 850–1,500 mg with glycated
hemoglobin (HbA1c) 7.5–11.5% at screening
were eligible for this double-blind, active-
controlled study. Patients were stabilized on
metformin XR 1,500 mg before randomization.
Patients with HbA1c 7–11% and fasting plasma
glucose (FPG) C126 mg/dL after a 4- 8-week
lead-in period were randomly assigned to
saxagliptin 5 mg ? metformin XR 1,500 mg or
metformin XR 500 mg ? metformin XR
1,500 mg (uptitrated metformin XR). The
primary end point was change from baseline
to week 4 in 24-h mean weighted glucose
(MWG). Secondary end points were changes
from baseline to week 4 in 2-h postprandial
glucose (PPG) and FPG.
Results: At week 4, the adjusted mean ± SE
change from baseline in 24-h MWG was
-19.0 ± 5.7 mg/dL (95% CI -30.3 to -7.6) for
saxagliptin ? metformin XR and -8.2 ± 6.0
mg/dL (95% CI -20.0 to 3.7) for uptitrated
metformin XR. Mean changes from baseline in
2-h PPG and FPG were numerically greater with
saxagliptin ? metformin XR versus uptitrated
metformin XR. The incidence of adverse
events was lower with saxagliptin ? metformin
XR (17.4%) versus uptitrated metformin
XR (31.9%) mainly due to differences in
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gastrointestinal adverse event incidence (2.2%
vs 10.6%, respectively). There were no reports of
confirmed hypoglycemia in either group.
Conclusion: In this 4-week study in patients
with T2DM inadequately controlled with
metformin monotherapy, saxagliptin added to
metformin XR demonstrated a trend for
improvement in measures of daily glycemic
control, with fewer gastrointestinal adverse
events, compared with uptitrated metformin.
Keywords: Efficacy; Glycemic control;
Metformin; Saxagliptin; Tolerability; Type 2
diabetes mellitus
INTRODUCTION
In patients with type 2 diabetes mellitus
(T2DM), long-term control of blood glucose
levels is necessary to help prevent the
development of microvascular and
macrovascular complications. Current
guidelines from the American Diabetes
Association/European Association for the
Study of Diabetes (ADA/EASD) recommend
that glycated hemoglobin (HbA1c) be
maintained at \7.0% in most patients but be
compatible with the patient’s preferences,
needs, and values, in line with the goal of
providing patient-centered care [1]. Guidelines
from the American Association of Clinical
Endocrinologists/American College of
Endocrinology (AACE/ACE) recommend a
stringent HbA1c target of 6.5% [2]. HbA1c is
influenced by increases in daily measures of
glucose levels including fasting plasma glucose
(FPG) and postprandial glucose (PPG), which
are discrete values for measures of daily glucose
levels. In addition, rapid daily fluctuations in
glucose levels have been implicated as
particularly important in contributing to
diabetes-related complications [3]. Because
average daily glucose measurements are
strongly correlated with HbA1c [4] and are
important parameters for physicians to make
therapeutic decisions, and because patients
understand FPG and PPG better than HbA1c
[5], estimation of mean daily glucose
parameters is critical. Twenty-four hour mean
weighted glucose (MWG) can be used to provide
an indication of the mean glucose exposure of
the body over an entire day [6].
The ADA/EASD position statement
recommends combination therapy when
HbA1c goals are not achieved or maintained
during approximately 3 months with
monotherapy [1]. However, uptitration of
monotherapy is often practiced rather than
addition of another agent [7, 8], which is
delayed by an average 27–35 months [7]. The
ADA/EASD and AACE/ACE recommend
metformin as first-line drug therapy for T2DM
[1, 2]. Metformin is a biguanide that helps
maintain glycemic control by suppressing
glucose production by the liver [1].
Gastrointestinal disturbances (diarrhea,
nausea, and vomiting) are the most common
adverse events reported with metformin
monotherapy, although the incidence is lower
with metformin extended release (XR) versus
metformin immediate release (IR) [9, 10].
Because T2DM is a progressive disease
associated with worsening hyperglycemia,
intensification of treatment over time through
combination therapy typically becomes
necessary for most patients to maintain
glycemic goals [1, 11]. After metformin is
used, various strategies to achieve glycemic
control can be applied. Antidiabetic
medications with complementary mechanisms
of action and differing safety and tolerability
profiles can help improve glycemic outcomes
with greater tolerability compared with
270 Diabetes Ther (2013) 4:269–283
123
uptitration of a single antihyperglycemic agent
to the maximum dose [1, 12, 13].
Saxagliptin is a dipeptidyl peptidase-4
(DPP-4) inhibitor with a mechanism of action
complementary to that of metformin. The DPP-
4 enzyme is involved in the degradation of the
incretin hormones glucagon-like peptide 1
(GLP-1) and glucose-dependent insulinotropic
peptide (GIP), both of which augment release of
insulin from the pancreas in a glucose-
dependent manner; GLP-1 also decreases
pancreatic glucagon secretion. By inhibiting
DPP-4 degradation of GLP-1 and GIP,
saxagliptin increases insulin secretion and
suppresses glucagon release, complementary
effects for controlling hyperglycemia [1, 14,
15]. DPP-4 inhibitors may also aid in beta-cell
preservation, as suggested by preclinical
evidence of inhibition of beta-cell apoptosis
and necrosis and stimulation of beta-cell
proliferation [16]. Saxagliptin is generally well
tolerated for the treatment of T2DM [17]. The
most commonly reported adverse events with
saxagliptin are upper respiratory tract infection,
urinary tract infection, and headache [18].
Saxagliptin is weight neutral and is not
associated with hypoglycemia when used as
monotherapy [17]; dose-adjustment from the
approved 5-mg dose is not required in patients
with hepatic impairment, but dose-reduction is
required in patients with moderate to severe
renal impairment and when coadministered
with strong inhibitors and inducers of
cytochrome P450 3A4 and 3A5 isoforms [17].
Postmarketing reports of pancreatitis have been
reported with DPP-4 inhibitors, including
saxagliptin [17, 18].
Saxagliptin has been shown to be efficacious
and generally well tolerated as add-on therapy in
patients with T2DM inadequately controlled
with metformin monotherapy [19, 20] so it
was theorized that addition of saxagliptin in
patients inadequately controlled with
metformin alone may improve efficacy and
tolerability compared with uptitration of
metformin. A previous study reported
significant improvements in HbA1c with the
addition of saxagliptin to metformin XR versus
uptitration of metformin XR over 18 weeks [12].
Here, findings are presented from a 4-week study
in which the clinical effects, including impact
on measures of daily glucose control, of adding
saxagliptin 5 mg to metformin XR 1,500 mg
were compared with those of uptitrating
metformin XR to the maximum daily dosage
of 2,000 mg in patients with T2DM whose
glucose levels were not adequately controlled
with metformin monotherapy.
MATERIALS AND METHODS
The study protocol for this international,
randomized, double-blind, phase 3b trial was
approved by the institutional review board and
independent ethics committee at each site, and
the study was conducted in accordance with
Good Clinical Practice, as defined by the
International Conference on Harmonisation.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients before being included in the study.
Men and women aged 18–78 years with
T2DM were eligible for the study if they had
been taking a stable daily dose of metformin IR
or XR C850 and B1,500 mg as monotherapy for
C8 weeks prescreening but had inadequate
glycemic control, defined as HbA1c 7.5–11.5%
at screening. At screening, all previous
metformin regimens were converted to
metformin XR such that all patients were
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taking metformin XR 1,500 mg once daily.
Patients also had to meet the following
inclusion criteria during the screening period:
HbA1c 7–11.5% at 4 weeks before randomization,
HbA1c 7–11% and FPG C126 mg/dL at 1 week
before randomization, fasting C-peptide
concentration C1.0 ng/mL at screening, and
body mass index B40 kg/m2 at screening.
Key exclusion criteria were symptoms of
poorly controlled T2DM, including but not
limited to marked polyuria and polydipsia,
with a [10% weight loss in the 3 months
prescreening or other signs or symptoms of
poorly controlled hyperglycemia; history of
diabetic ketoacidosis or hyperosmolar
nonketotic coma; and insulin therapy within
1 year of screening, except for during a
hospitalization or use in gestational diabetes.
Patients were also excluded if they had a
significant cardiovascular history, defined as a
history of myocardial infarction, coronary
angioplasty or bypass graft(s), valvular disease
or repair, unstable angina pectoris, transient
ischemic attack, or cerebrovascular accident
B6 months before study entry; or congestive
heart failure, defined as New York Heart
Association class III and IV and/or known left
ventricular ejection fraction B40%. Also
excluded were patients with chronic or
repeated intermittent corticosteroid treatment
and a history of unstable or rapidly progressing
renal disease; an unstable major psychiatric
disorder; a history of hemoglobinopathies;
donation of blood or plasma to a blood bank
B3 months prescreening; and active liver
disease or infection or clinically significant
abnormalities on screening tests of hepatic,
renal, endocrine, metabolic, or hematologic
function. Women who were pregnant or
breastfeeding were excluded, and sexually
active women of childbearing potential and
fertile men whose partners were women of
childbearing potential were required to
use an acceptable method of contraception
throughout the study.
After screening, eligible patients completed a
single-blind, lead-in period, during which they
received metformin XR 1,500 mg (Fig. 1). The
lead-in period was 8 weeks for patients who
were currently receiving metformin
IR B1,500 mg or metformin XR\1,500 mg and
4 weeks for patients already receiving
metformin XR 1,500 mg. After completing the
lead-in period, patients with HbA1c 7–11% and
FPG C126 mg/dL and good adherence
(80–120%) with study medication were
randomly assigned in a 1:1 ratio to treatment
with double-blind saxagliptin 5 mg added to
open-label metformin XR 1,500 mg or double-
blind metformin XR 500 mg added to open-
label metformin XR 1,500 mg (uptitrated
metformin XR 2,000 mg). Randomization was
accomplished using an interactive voice-
response system and a blocked randomization
schedule with block size of 2. All study
medication was taken once daily with the
evening meal.
Patients completed 24-h domicile visits at
randomization and at the end of the 4-week
treatment period for assessment of 24-h MWG.
During each domicile visit, patients received
standardized meals. The standardized evening
meal consisted of two 8-ounce containers of
Boost Plus (Nestle´ S.A., Vevey, Switzerland)
and 1 Zone Perfect bar (Abbott Laboratories,
Columbus, OH, USA). The Boost Plus energy
drinks provided 360 calories per 8-ounce
container, with 14 g protein, 45 g
carbohydrate, and 14 g fat; each Zone Perfect
bar provided 200 calories, with 14 g protein,
25 g carbohydrate, and 6 g fat, for a meal total
of 920 calories, with 42 g protein, 115 g
carbohydrate, and 34 g fat. Breakfast and
lunch were administered based on a sample
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menu created by a registered dietician and were
to be followed exactly on both domicile days.
The total caloric intake per 24 h during the
domicile visit was 2,440 calories.
Blood for assessment of glucose level was
drawn at 30 and 5 min before each meal and 30,
60, 120, 180, and 240 min after each meal
(240 min after the evening meal only), and at
midnight, 3 a.m., and 24 h after the first blood
draw.
All prior and current medications at
screening and concomitant medications taken
during the study were recorded. Patients using
herbal or over-the-counter glucose-lowering
agents were allowed to continue with the
medications provided that doses remained
stable throughout the study, but they could
not begin treatment with these preparations
during the study. Antihyperglycemic
medications other than study medication were
not permitted, with the exception of insulin
during a hospitalization for other causes. Potent
cytochrome P450 3A4 inducers and HIV
antivirals were prohibited. Treatment with any
systemic corticosteroid could not be started
during the study.
Efficacy Assessments
The primary efficacy end point was the change
from baseline to week 4 in 24-h MWG. The 24-h
MWG was estimated by dividing the area under
the 24-h glucose concentration curve by 24.
The secondary efficacy end points were
change from baseline to week 4 in 2-h PPG
(2-h after the evening meal) and FPG (immediately
before breakfast). The tertiary efficacy end point
was the change in HbA1c from baseline to week 4.
All glucose measurements for assessment of
efficacy end points were processed at a central
laboratory.
Safety and Tolerability Assessments
All adverse events, serious adverse events, and
discontinuations due to adverse events were
Fig. 1 Study design. DB Double blind, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IR immediate release,
MET XR metformin extended release, MWG mean weighted glucose, OL open label, SAXA saxagliptin
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recorded. Safety and tolerability also were
assessed by evaluating changes in 12-lead
electrocardiograms (ECGs), vital signs, and
clinical laboratory tests.
Statistical Analysis
A sample size of 36 patients per group was
estimated to provide 90% power to detect a
difference of 18 mg/dL in MWG from baseline
to week 4 between the two treatment groups.
Assuming approximately 20% of patients would
discontinue without a valid efficacy assessment
at week 4, 90 patients needed to be randomized.
The change from baseline to week 4 in 24-h
MWG (primary efficacy end point) was analyzed
in the randomized data set (all randomized
patients who took C1 dose of study medication)
for patients who had a baseline measurement
and a post-randomization measurement for the
time point analyzed using analysis of
covariance (ANCOVA), including treatment
group, baseline value, and country in the
model.
The change from baseline to week 4 in 2-h
PPG (secondary efficacy end point) was analyzed
using the same ANCOVA used for the primary
efficacy end point. Change from baseline to
week 4 in FPG (secondary efficacy end point)
was analyzed using ANCOVA, with treatment
group, baseline value, and country in the model,
and using last-observation-carried-forward
methods. The change from baseline to week 4
in HbA1c (tertiary efficacy end point) was
analyzed using ANCOVA, with treatment
group, baseline values, and country in the model.
Statistical testing of the primary and
secondary efficacy end points was conducted
sequentially to control the type I error rate at
the 0.05 level. Safety analyses are presented
descriptively, using data from all patients who
took C1 dose of study medication.
RESULTS
This study was conducted at 23 sites (14 in the
USA, 4 in Israel, 3 in Mexico, and 2 in Argentina)
between August 2009 and May 2010. Of 126
patients entering the lead-in period; 93 patients
were randomized and treated (Fig. 2). Ninety
patients (96.8%) completed the 4-week
treatment period. One patient in each group
discontinued because they withdrew consent,
and 1 patient in the saxagliptin ? metformin XR
group died on day 9 from chronic ischemic heart
disease with cardiomegaly. This death was not
considered by the investigator to be related to
study drug. Treatment groups were generally
balanced with regard to demographic and
baseline clinical characteristics (Table 1). Most
patients were white, and there were similar
proportions of men and women. The mean
duration of diabetes was longer in the
saxagliptin ? metformin XR group, 6.2 years,
than in the uptitrated metformin XR group,
5.1 years.
All patients had received metformin before
study entry. One patient in the saxagliptin ?
metformin XR group had previously received
pioglitazone ? metformin and 1 patient in the
uptitrated metformin XR group had received
rosiglitazone ? metformin. The proportion of
patients receiving concomitant medications
during the study was similar in each treatment
group (54.3% for saxagliptin ? metformin XR
and 53.2% for uptitrated metformin XR). The
most commonly used concomitant medications
in the saxagliptin ? metformin XR and
uptitrated metformin XR groups were
cardiovascular system medications, primarily
antihypertensives (32.6% and 34.0%,
respectively), and nervous system medications,
including antiepileptics, anxiolytics,
antivertigo, and opioids (23.9% and 36.2%,
respectively).
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Efficacy
At baseline, mean ± SE 24-h MWG was
191.3 ± 6.3 mg/dL in the saxagliptin ?
metformin XR group and 192.0 ± 6.1 mg/dL in
the uptitrated metformin XR group. The
adjusted mean ± SE change from baseline to
week 4 was -19.0 ± 5.7 mg/dL (95% CI -30.3
to -7.6) for saxagliptin ? metformin XR and
-8.2 ± 6.0 mg/dL (95% CI -20.0 to -3.7) for
uptitrated metformin XR. The mean ± SE
between-group difference was -10.8 ± 7.01
mg/dL (95% CI -24.8 to 3.2; P = 0.1278) for
saxagliptin ? metformin XR versus uptitrated
metformin XR (Table 2). In keeping with the
sequential statistical analysis procedure used in
this study, because between-group differences
in the primary end point did not reach
statistical significance, the significance of
differences in secondary and tertiary efficacy
end points was not calculated.
The 24-h glucose profile was comparable
between groups at baseline (Fig. 3a). At week 4,
between-group differences were observed, with
lower glucose levels recorded in patients
receiving saxagliptin ? metformin XR
compared with patients receiving uptitrated
metformin XR (Fig. 3b). The mean change
from baseline in 24-h glucose levels at week 4
was generally greater at all but one time point
with saxagliptin ? metformin XR than with
uptitrated metformin XR (Fig. 3c).
At week 4, the adjusted mean ± SE change
from baseline for 2-h PPG was greater with
saxagliptin ? metformin XR than with
uptitrated metformin XR (Table 3); the
mean ± SE between-group difference was
-31.1 ± 11.8 mg/dL (95% CI -54.6 to -7.7).
Fig. 2 Patient disposition. MET XR metformin extended release, SAXA saxagliptin
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For FPG, the adjusted mean ± SE change from
baseline was also greater for saxagliptin ?
metformin XR than for uptitrated metformin
XR (Table 3); the mean ± SE between-group
difference was -5.7 ± 7.2 mg/dL (95% CI
-20.0 to 8.5). The adjusted mean ± SE change
from baseline for HbA1c was slightly greater for
saxagliptin ? metformin XR than for uptitrated
metformin XR (Table 3); the mean ± SE
between-group difference was -0.1 ± 0.1%
(95% CI -0.3 to 0.0).
During the screening period, the mean
HbA1c decreased in patients that were to be
subsequently randomized to the two groups at
week -4, after all of these patients were
switched to metformin XR 1,500 mg (Fig. 4).
However, mean HbA1c continued to decline
from week -4 to week 0 (pre-randomization) in
the uptitrated metformin XR group but
remained stable in the saxagliptin ?
metformin XR group. Mean HbA1c continued
to decrease in both groups during the double-
blind treatment period and was similar in both
groups at week 4, despite a higher mean HbA1c
at randomization in the saxagliptin ?
metformin group.







Men 25 (54.3) 22 (46.8)
Women 21 (45.7) 25 (53.2)
Age, years
Mean ± SD 53.9 ± 9.4 50.6 ± 9.7
Range 30–72 29–68
Age group, n (%)
\65 years 40 (87.0) 45 (95.7)
C65 years 6 (13.0) 2 (4.3)
Race, n (%)
White 43 (93.5) 45 (95.7)
Black 3 (6.5) 2 (4.3)
Ethnicity, n (%)
Hispanic/Latino 16 (34.8) 17 (36.2)
Not Hispanic/Latino 8 (17.4) 8 (17.0)
Not reported 22 (47.8) 22 (46.8)
Geographic region, n (%)
North America 24 (52.2) 25 (53.2)
Latin America 18 (39.1) 20 (42.6)
Europe 4 (8.7) 2 (4.3)
Mean ± SD weight, kg 91.3 ± 18.4 86.9 ± 15.2
Mean ± SD BMI, kg/m2 32.5 ± 5.1 31.1 ± 4.3
Mean ± SD duration of
diabetes, years
6.2 ± 4.5 5.1 ± 3.9
HbA1c, %
Mean ± SD 8.6 ± 0.9 8.4 ± 0.9
Categorized, n (%)
\8% 11 (23.9) 16 (34.0)
C8–\9% 20 (43.5) 20 (42.6)







Mean ± SD 2-h PPG,
mg/dL
281.3 ± 51.6 283.3 ± 66.1
Mean ± SD FPG,
mg/dL
163.5 ± 32.3 164.2 ± 36.2
BMI Body mass index, FPG fasting plasma glucose
(immediately before breakfast), HbA1c glycated
hemoglobin, MET XR metformin extended release, PPG
postprandial glucose (2 h after the evening meal), SAXA
saxagliptin, SD standard deviation
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Safety and Tolerability
Adverse events of any causality, were reported
by 8 (17.4%) patients in the
saxagliptin ? metformin XR group, compared
with 15 (31.9%) in the uptitrated metformin XR
group (Table 4). No serious adverse events
occurred in either treatment group. The single
death that occurred during the study was
related to chronic ischemic heart disease in a
patient in the saxagliptin ? metformin XR
group and was not considered related to study
drug. No patient in either treatment group
discontinued the current study because of an
adverse event. Cough was the only adverse
event that occurred in C5% of patients in
either treatment group (n = 3 [6.5%] in the
saxagliptin ? metformin XR group and n = 0
[0%] of the uptitrated metformin XR group).
Although the incidence of gastrointestinal
adverse events is reported to be lower with
metformin XR than with metformin IR [21], the
proportion of patients experiencing any
gastrointestinal adverse event was higher with
uptitrated metformin XR (n = 5 [10.6%]) than
with saxagliptin ? metformin XR (n = 1
[2.2%]). Excluding hypoglycemia, treatment-
related adverse events occurred in only 1
patient, who was in the uptitrated metformin
XR group. This patient had 3 gastrointestinal
adverse events (upper abdominal pain, diarrhea,
and nausea).
There were no reported adverse events of
lymphopenia, thrombocytopenia, localized
edema, hypersensitivity, pancreatitis, jaundice,
or skin-related adverse events during the double-
blind treatment period. Few infections were
reported in either treatment group (n = 2,
[4.3%] in each group). There were no reports of
confirmed hypoglycemia (defined as a fingerstick
glucose value B50 mg/dL in the presence of
symptoms) in any patient from either group.
Reported hypoglycemia was recorded for 1
patient (2.2%) in the saxagliptin ? metformin
XR group and in 2 patients (4.3%) in the
uptitrated metformin XR group.
No electrocardiogram (ECG) abnormalities,
clinically meaningful changes in blood
pressure, or clinically relevant changes in
laboratory test results, including those for liver
function, were reported in either treatment
group.






Baseline mean ± SE, mg/dL 191.3 ± 6.3 192.0 ± 6.1
Adjusted mean ± SE change from baseline, mg/dL -19.0 ± 5.7 -8.2 ± 6.0
95% CI -30.3 to -7.6 -20.3 to 3.7
Mean ± SE difference vs uptitrated MET XR, mg/dL -10.8 ± 7.01
95% CI for difference -24.8 to 3.2
P value for difference 0.1278
CI Conﬁdence interval, MET XR metformin extended release, MWG mean weighted glucose, SAXA saxagliptin, SE
standard error
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DISCUSSION
This 4-week study was carried out to compare
the impact of adding saxagliptin 5 mg to
metformin XR 1,500 mg versus uptitration of
metformin XR to 2,000 mg on measures of daily
glucose control, including 24-h MWG, 2-h PPG,
and FPG in patients with T2DM whose glucose
levels were not adequately controlled with
metformin monotherapy. Although HbA1c is
an important parameter for examining glycemic
control over time, it provides limited benefit in
understanding the daily fluctuations
experienced by patients. This study evaluated
the impact of 2 commonly used paradigms of
Fig. 3 The 24-h glucose proﬁle at a baseline and b week 4
and mean change from baseline at c week 4 in 24-h glucose
proﬁle for patients receiving SAXA ? MET XR and for
patients receiving uptitrated MET XR. MET XR Metfor-
min extended release, SAXA saxagliptin
b
Table 3 Change in secondary efﬁcacy variables from baseline to week 4
SAXA 1MET XR (n5 46) Uptitrated MET XR (n5 47)
2-h PPG, mg/dL
N 44 46
Baseline mean ± SE 229.7 ± 9.1 234.0 ± 10.3
Adjusted mean ± SE change from baseline -31.4 ± 9.7 -0.2 ± 10.1
95% CI -50.6 to -12.1 -20.3 to 19.8
Mean ± SE difference vs uptitrated MET XR -31.1 ± 11.8
95% CI for difference -54.6 to -7.7
FPG, mg/dL
n 45 47
Baseline mean ± SE 162.9 ± 4.8 164.2 ± 5.3
Adjusted mean ± SE change from baseline -9.3 ± 5.9 -3.6 ± 6.2
95% CI -21.1 to 2.5 -15.8 to 8.7
Mean ± SE difference vs uptitrated MET XR -5.7 ± 7.2
95% CI for difference -20.0 to 8.5
HbA1c, %
n 43 43
Baseline mean ± SE 8.6 ± 0.13 8.3 ± 0.12
Adjusted mean ± SE change from baseline -0.4 ± 0.1 -0.2 ± 0.1
95% CI -0.5 to -0.2 -0.4 to -0.1
Mean ± SE difference vs uptitrated MET XR -0.1 ± 0.1
95% CI for difference -0.3 to 0.0
CI Conﬁdence interval, FPG fasting plasma glucose (immediately before breakfast), HbA1c glycated hemoglobin, MET XR
metformin extended release, PPG postprandial glucose (2 h after the evening meal), SAXA saxagliptin, SE standard error
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diabetes treatment in patients inadequately
controlled with metformin: addition of drugs
with complementary mechanisms of action and
uptitration of existing therapy. The results
indicate that short-term treatment with
saxagliptin 5 mg added to metformin XR
1,500 mg once daily is generally well tolerated
and may provide greater improvements in
glycemic control compared with uptitrating
metformin XR from 1,500 to 2,000 mg. The
decreases in mean plasma glucose levels with
the addition of saxagliptin were most
noteworthy after meals, consistent with the
incretin-mediated mechanism of action of
saxagliptin.
The observation that the difference between
saxagliptin ? metformin XR and uptitrated
metformin XR groups in the primary efficacy
end point did not reach statistical significance
may reflect the higher-than-expected variability
in 24-h MWG data within each treatment
group. In turn, it is possible that this
variability may result from inequalities
between the treatment groups at baseline. As
shown in Fig. 4, patients who were later
assigned to the saxagliptin group appeared to
have a stable HbA1c during the lead-in period,
whereas those later assigned to the metformin
XR uptitration group appeared to have a
continuing decline in HbA1c before
randomization, suggesting their glycemic
status had not reached equilibrium. Thus, it is
possible that the lead-in period may not have
been sufficient to create a stable baseline. The
number of patients who had their metformin
XR dose uptitrated during the lead-in period
was balanced between the two groups. In a
4-week, placebo-controlled trial of similar
design that enrolled patients with
demographic and clinical characteristics
similar to those in our study,
saxagliptin ? metformin XR produced
significantly greater decreases in 24-h MWG,
compared with placebo (adjusted mean ± SE
change from baseline to week 4, -13.8 ± 3.0 vs
3.0 ± 3.0 mg/dL; 95% CI for difference, -25.1 to
Table 4 Summary of adverse events
Patients, n (%)
SAXA1MET





Any 8 (17.4%) 15 (31.9%)
Treatment related 0 2 (4.3%)
Serious adverse events
Any nonfatal 0 0
Treatment related 0 0
Adverse events leading to
discontinuation
Any 0 0
Serious adverse event 0 0
Deaths 1a 0
MET XR Metformin extended release, SAXA saxagliptin
a Cause of death was chronic ischemic heart disease with













SAXA + MET XR
Uptitrated MET XR
Screening Week –4 Week –1 Pre-
randomization
Week 4
Fig. 4 Mean glycated hemoglobin (HbA1c) from screen-
ing to week 4. MET XR Metformin extended release,
SAXA saxagliptin
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-8.5; P = 0.0001) [22]. Differences in other
glycemic measures, including 2-h PPG, mean
daily glucose, and 2-day average FPG, were also
significantly greater with saxagliptin ?
metformin XR, compared with placebo. In
contrast with the current study, the patients in
that study did not change their metformin dose
during the lead-in period [22].
The interpretation of the HbA1c results is
limited by the short duration of the current
study. HbA1c is a more stable end point than
MWG, and with a longer duration of treatment,
differences in effect on HbA1c between
saxagliptin ? metformin XR and uptitrated
metformin XR would be expected to be
demonstrated, as reported in a similarly
designed 18-week study [12]. In that study, the
decrease in HbA1c at week 18 was significantly
greater with saxagliptin ? metformin XR,
compared with uptitrated metformin XR
(adjusted mean change from baseline, -0.88%
vs -0.35%; 95% CI for difference, -0.73 to
-0.31; P\0.0001). In this longer trial, 24-h
MWG was not an end point [12]. Given that the
design of that study was almost identical to the
design of the current study, it is likely that add-
on therapy with saxagliptin versus uptitration
of metformin would have resulted in significant
decreases in HbA1c if the current study had
extended beyond 4 weeks.
Along with considerations of efficacy,
tolerability, and safety, it is also important to
include cost-effectiveness as a factor in the
decision to add saxagliptin to metformin XR
therapy. To the authors knowledge, the cost-
effectiveness of saxagliptin ? metformin XR,
compared with uptitrated metformin XR has
yet to be assessed. However, recent studies
performed in Germany and Sweden have
reported saxagliptin plus metformin to be
cost-effective compared with metformin plus
sulfonylurea, based on relatively greater
improvements in quality-adjusted life years
[23, 24].
The current study is limited in that it
presents the outcomes achieved in a small
number of patients, examining a nonstandard,
mechanistic end point after only 4 weeks of
treatment. Therefore, these results may not be
applicable to patients receiving longer-term
treatment.
CONCLUSION
Short-term treatment with saxagliptin 5 mg
added to metformin XR 1,500 mg once daily
was generally well tolerated in patients with
T2DM who had inadequate glycemic control
with metformin monotherapy. Saxagliptin ?
metformin XR produced numerically greater,
although not statistically significant, decreases
in 24-h MWG, 2-h PPG, and FPG with fewer
gastrointestinal adverse events, compared with
uptitrating metformin XR from 1,500 to
2,000 mg.
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